The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities

Recent progress in the development of small-molecule glucagon receptor antagonists

(2015) Matthew F. Sammons et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes

(2015) Rachel J. Perry et al.   CELL

Hepatic Mitochondrial Pyruvate Carrier 1 Is Required for Efficient Regulation of Gluconeogenesis and Whole-Body Glucose Homeostasis

(2015) Lawrence R. Gray et al.   Cell Metabolism

Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function

(2015) Annayya R. Aroor et al.   DIABETES

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

(2015) B. Bode et al.   DIABETES OBESITY & METABOLISM

Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes

(2015) Hiroyuki Kato et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice

(2015) Su-Yeon Lee et al.   HEPATOLOGY

Effect of Vildagliptin on Hepatic Steatosis

(2015) Mavin Macauley et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon receptor antagonism induces increased cholesterol absorption

(2015) Hong-Ping Guan et al.   JOURNAL OF LIPID RESEARCH

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ceramides – Lipotoxic Inducers of Metabolic Disorders

(2015) Bhagirath Chaurasia et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance

(2015) Barbara Bernardo et al.   Scientific Reports

Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes

(2014) Raymond E. Soccio et al.   Cell Metabolism

Abrogating Monoacylglycerol Acyltransferase Activity in Liver Improves Glucose Tolerance and Hepatic Insulin Signaling in Obese Mice

(2014) A. M. Hall et al.   DIABETES

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

(2014) Eli M. Roth et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Diabetic dyslipidemia

(2014) Liya Wu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

(2014) Anila K. Madiraju et al.   NATURE

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

(2014) Anders Berg Jørgensen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting APOC3 in the Familial Chylomicronemia Syndrome

(2014) Daniel Gaudet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats

(2014) Derek M. Erion et al.   PLoS One

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

(2014) Xing-Chun Wang   WORLD JOURNAL OF GASTROENTEROLOGY

A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans

(2014) Nicholas J. Timpson et al.   Nature Communications

Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice

(2013) Zhuofeng Lin et al.   Cell Metabolism

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer

(2013) J R Colca et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Global estimates of diabetes prevalence for 2013 and projections for 2035

(2013) L. Guariguata et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes

(2013) Jeffrey A Pfefferkorn   Expert Opinion on Drug Discovery

Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose

(2013) V. Sazonov et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Mechanisms for Insulin Resistance: Common Threads and Missing Links

(2012) Varman T. Samuel et al.   CELL

PPARγ agonists Induce a White-to-Brown Fat Conversion through Stabilization of PRDM16 Protein

(2012) Haruya Ohno et al.   Cell Metabolism

Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study

(2012) H. Denison et al.   DIABETES OBESITY & METABOLISM

Intrahepatic Diacylglycerol Content Is Associated With Hepatic Insulin Resistance in Obese Subjects

(2012) Faidon Magkos et al.   GASTROENTEROLOGY

New lipid-lowering drugs: an update

(2012) A. S. Wierzbicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver

(2012) Angela M. Hall et al.   JOURNAL OF LIPID RESEARCH

Cholesterol-lowering blockbuster candidates speed into Phase III trials

(2012) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear receptor PPAR -regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis

(2012) Y. J. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2011) Philip J. Barter et al.   CIRCULATION

Heart Disease and Stroke Statistics—2012 Update

(2011) et al.   CIRCULATION

Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance

(2011) Hui-Young Lee et al.   HEPATOLOGY

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

(2011) David Preiss   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases

(2011) Jingsong Cao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissociation of Inositol-requiring Enzyme (IRE1α)-mediated c-Jun N-terminal Kinase Activation from Hepatic Insulin Resistance in Conditional X-box-binding Protein-1 (XBP1) Knock-out Mice

(2011) Michael J. Jurczak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Coenzyme A: Diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets

(2010) Toshihiro Yamamoto et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase

(2010) Shani Ben-Shlomo et al.   JOURNAL OF HEPATOLOGY

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease

(2010) Kitt Falk Petersen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Standards of Medical Care in Diabetes--2009

(2009)   DIABETES CARE

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes

(2009) R. A. DeFronzo et al.   DIABETES CARE

Dyslipidemia in type 2 diabetes mellitus

(2009) Arshag D Mooradian   Nature Reviews Endocrinology

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

(2009) William W. Shields et al.   Therapeutic Advances in Gastroenterology

Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome

(2008) Martin Adiels et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance

(2008) J. M. Haus et al.   DIABETES

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY